Italo Corsale1, Paolo Carrieri2, Jacopo Martellucci3, Alessandro Piccolomini4, Luigi Verre4, Marco Rigutini5, Sonia Panicucci5. 1. General Surgery Unit, SS. Cosma e Damiano Hospital, Pescia, Italy. itcorsal@hotmail.it. 2. General, Emergency and Mini-invasive surgery, Careggi University Hospital, Florence, Italy. 3. General Surgery Unit, Borgo San Lorenzo Hospital, Borgo San Lorenzo, Italy. 4. Unit of General Surgery 2, Policlinico Le Scotte, Siena, Italy. 5. General Surgery Unit, SS. Cosma e Damiano Hospital, Pescia, Italy.
Abstract
PURPOSE: We evaluated the efficacy of new flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) to reduce bleeding from I-III degrees hemorrhoidal disease in the short and medium time. METHODS:One hundred fifty-four consecutive patients with hemorrhoidal disease recruited in four colorectal units were enrolled to the study. Exclusion criteria were allergy to the flavonoids, inflammatory bowel disease, obstructed defecation syndrome, pregnancy and puerperium, associated anal disease or hemorrhoidal thrombosis, proctologic surgical procedures within 1 year before recruitment, contemporary cancer or HIV, previous pelvic radiotherapy, patients receiving oral anticoagulant therapy, or contemporary administration of other therapy for hemorrhoids. Patients with inability to understand the study or mental disorders were also excluded. RESULTS:Seventy-eight were randomized to receive the mixture of diosmin, troxerutin, rutin, hesperidin, and quercetin (study group, SG), and 76 a mixture of diosmin in combination with hesperidin, diosmetin, isoroifolin, and linarin in purified micronized fraction (control group, CG). Bleeding, number of pathological piles, and Golligher's grade were assessed at each scheduled visit and compared using the Chi-square test. During the study period, bleeding improved after 1 and 6 months both in the SG (79.5 and 70.5%) and in the CG (80.2 and 75%) without significant differences between two groups. Satisfaction degree after 6 months was greater in the patients of the SG (4.05) towards the CG (3.25): this result was statistical significant (p 0.003). CONCLUSIONS: Use of flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) is a safe and effective mean of managing bleeding from hemorrhoidal disease and minimal adverse events are reported.
RCT Entities:
PURPOSE: We evaluated the efficacy of new flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) to reduce bleeding from I-III degrees hemorrhoidal disease in the short and medium time. METHODS: One hundred fifty-four consecutive patients with hemorrhoidal disease recruited in four colorectal units were enrolled to the study. Exclusion criteria were allergy to the flavonoids, inflammatory bowel disease, obstructed defecation syndrome, pregnancy and puerperium, associated anal disease or hemorrhoidal thrombosis, proctologic surgical procedures within 1 year before recruitment, contemporary cancer or HIV, previous pelvic radiotherapy, patients receiving oral anticoagulant therapy, or contemporary administration of other therapy for hemorrhoids. Patients with inability to understand the study or mental disorders were also excluded. RESULTS: Seventy-eight were randomized to receive the mixture of diosmin, troxerutin, rutin, hesperidin, and quercetin (study group, SG), and 76 a mixture of diosmin in combination with hesperidin, diosmetin, isoroifolin, and linarin in purified micronized fraction (control group, CG). Bleeding, number of pathological piles, and Golligher's grade were assessed at each scheduled visit and compared using the Chi-square test. During the study period, bleeding improved after 1 and 6 months both in the SG (79.5 and 70.5%) and in the CG (80.2 and 75%) without significant differences between two groups. Satisfaction degree after 6 months was greater in the patients of the SG (4.05) towards the CG (3.25): this result was statistical significant (p 0.003). CONCLUSIONS: Use of flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) is a safe and effective mean of managing bleeding from hemorrhoidal disease and minimal adverse events are reported.
Authors: P Alonso; M Marzo; J J Mascort; A Hervás; L Viñas; J Ferrús; J Ferrándiz; L López-Rivas; X Bonfill; J M Piqué Journal: Gastroenterol Hepatol Date: 2002-12 Impact factor: 2.102
Authors: David E Rivadeneira; Scott R Steele; Charles Ternent; Sridhar Chalasani; W Donald Buie; Janice L Rafferty Journal: Dis Colon Rectum Date: 2011-09 Impact factor: 4.585
Authors: P Alonso-Coello; Q Zhou; M J Martinez-Zapata; E Mills; D Heels-Ansdell; J F Johanson; G Guyatt Journal: Br J Surg Date: 2006-08 Impact factor: 6.939
Authors: Yuri Shelygin; Zoran Krivokapic; S A Frolov; I V Kostarev; V L Astashov; S V Vasiliev; A V Lakhin; G V Rodoman; A O Soloviev; Y M Stoyko; A G Khitaryan; I A Nechay Journal: Curr Med Res Opin Date: 2016-08-25 Impact factor: 2.580
Authors: I Giannini; A Amato; L Basso; N Tricomi; M Marranci; G Pecorella; S Tafuri; D Pennisi; D F Altomare Journal: Tech Coloproctol Date: 2015-04-19 Impact factor: 3.781
Authors: Erin C Mooney; Sara E Holden; Xia-Juan Xia; Yajie Li; Min Jiang; Camille N Banson; Bin Zhu; Sinem Esra Sahingur Journal: Front Immunol Date: 2021-11-26 Impact factor: 7.561